MarketCapExport financials
Co-Diagnostics (CODX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Co-Diagnostics Income Statement 2025-2011 | CODX
Brief overview of profit and loss at Co-Diagnostics
The figures are compared over a five-year interval. Revenue at Co-Diagnostics moved from $74.6 million in 2020 to $622 thousand in 2025. The cumulative result was −99.2%, corresponding to roughly −61.6% per year. Sales followed a declining trajectory over the five years.
The gross result shifted from $58 million to $400 thousand, or −99.3%. There was no major divergence between sales and cost of revenue. Comparing the endpoints gives gross margins of 77.7% and 64.3%. The business retained less gross profit from each unit of revenue.
Over the period, EBITDA shifted from 41.8 million dollars to −49.1 million dollars, a change of −217.3%. Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin was 56.1% at the start and −7881% at the end. A lower EBITDA share weakens the quality of the result.
Across the five years, the net result shifted from 42.5 million dollars to −46.9 million dollars. Profit turned into a loss, the most concerning signal in the results.
The five-year change in capitalization reached −98.4%: from 361 million dollars to 5.9 million dollars. The decline in value indicates softer investor confidence.
Overall conclusion
The current trajectory does not yet confirm a sustainable recovery. Caution is warranted because of lower investor confidence, weaker gross profitability and declining net profitability. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Co-Diagnostics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
5.85 M | 4.45 M | 34.9 M | 93.5 M | 258 M | 361 M | 45.2 M | 28 M | 32.1 M | - | - | - | - | - | - |
Shares |
1.33 M | 1.01 M | 29.3 M | 31.5 M | 28.9 M | 28.1 M | 16.8 M | 12.5 M | 11 M | - | - | - | - | - | - |
Historical Prices |
4.4 | 4.4 | 1.19 | 2.97 | 8.93 | 9.3 | 0.895 | 1.49 | 2.64 | - | - | - | - | - | - |
Net Income |
-46.9 M | -37.6 M | -35.3 M | -14.2 M | 36.7 M | 42.5 M | -6.2 M | -6.27 M | -6.96 M | -1.93 M | -2.04 M | - | - | - | - |
Revenue |
622 K | 3.92 M | 6.81 M | 34.2 M | 97.9 M | 74.6 M | 215 K | 39.9 K | 7.66 K | - | 10 K | - | - | - | - |
Cost of Revenue |
222 K | 999 K | 4.18 M | 5.48 M | 11.6 M | 16.6 M | 112 K | 9.39 K | 302 | - | - | - | - | - | - |
Gross Profit |
400 K | 2.92 M | 2.63 M | 28.7 M | 86.3 M | 58 M | 103 K | 30.5 K | 7.36 K | - | - | - | - | - | - |
Operating Income |
-50.2 M | -40.1 M | -42.7 M | -27 M | 46.1 M | 41.7 M | -5.89 M | -6.12 M | -4.56 M | -1.69 M | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | 106 K | -154 K | 310 K | 241 K | - | - | - | - | - |
EBITDA |
-49.1 M | -38.7 M | -41.5 M | -25.7 M | 46.4 M | 41.8 M | -5.83 M | -6.07 M | -4.52 M | -1.65 M | -1.92 M | - | - | - | - |
Operating Expenses |
50.6 M | 43 M | 45.3 M | 55.7 M | 40.2 M | 16.3 M | 6 M | 6.15 M | 4.57 M | - | 1.98 M | - | - | - | - |
General and Administrative Expenses |
9.06 M | 16.2 M | 14.3 M | 14.3 M | 11.6 M | 8.28 M | 3.5 M | 3.57 M | 3.1 M | 797 K | 847 K | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Co-Diagnostics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
6.27 M | 4.31 M | 2.25 M | - | 37.9 M | 33.1 M | 32 M | 33.1 M | 30.5 M | 30.1 M | 29.8 M | 31.3 M | 29.4 M | 29.1 M | 29.5 M | 30.9 M | 31.3 M | 32.5 M | 33.9 M | 33.8 M | 28.9 M | 28.8 M | 28.7 M | 28.6 M | 28.1 M | 27.6 M | 22.8 M | 17.3 M | 17.3 M | 17 M | 16.1 M | 12.9 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 11.8 M | 9.88 M | 9.88 M | 9.88 M | 9.88 M | 9.88 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-6.31 M | -6.28 M | -9.14 M | - | -5.89 M | -7.73 M | -7.53 M | - | -9.7 M | -7.6 M | -9.31 M | - | -5.98 M | -8.92 M | -5.76 M | - | -1.36 M | -2.69 M | 11.7 M | - | 11.5 M | 9.79 M | 7.9 M | - | 15.7 M | 15 M | -1.07 M | - | -1.75 M | -1.34 M | -1.37 M | - | -1.64 M | -1.37 M | -1.31 M | - | -3.89 M | -855 K | -706 K | - | -450 K | -443 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
283 K | 166 K | 146 K | - | 145 K | 163 K | 50.3 K | - | 641 K | 2.66 M | 468 K | - | 2.46 M | 198 K | 602 K | - | 5.09 M | 5.02 M | 22.7 M | - | 30.1 M | 27.4 M | 20 M | - | 21.8 M | 24 M | 1.55 M | - | 41.4 K | 61.6 K | 3.4 K | - | 9.7 K | 9.7 K | 9.7 K | - | 2.6 K | 2.47 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
303 K | 45.3 K | 194 K | - | 26.3 K | 32.1 K | 21.6 K | - | 297 K | 212 K | 235 K | - | 256 K | 459 K | 502 K | - | 768 K | 915 K | 3.28 M | - | 3.31 M | 2.5 M | 3.27 M | - | 5.82 M | 5.98 M | 482 K | - | 20.4 K | 38.8 K | 452 | - | - | - | - | - | 302 | 302 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
-20.5 K | 121 K | -47.8 K | - | 119 K | 131 K | 28.7 K | - | 344 K | 2.44 M | 233 K | - | 2.2 M | -261 K | 99.7 K | - | 4.33 M | 4.11 M | 19.4 M | - | 26.8 M | 24.9 M | 16.8 M | - | 16 M | 18.1 M | 1.07 M | - | 21.1 K | 22.8 K | 2.95 K | - | 9.7 K | 9.7 K | 9.7 K | - | 2.6 K | 2.16 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-6.27 M | -6.2 M | -9.21 M | - | -7.01 M | -8.06 M | -8.55 M | - | -10.2 M | -7.68 M | -10.3 M | - | -8.94 M | -12 M | -9.95 M | - | -6.54 M | -4.15 M | 9.82 M | - | 13.6 M | 11.8 M | 10.3 M | - | 12 M | 14.7 M | -1.08 M | - | -1.65 M | -1.37 M | -1.25 M | - | -1.66 M | -1.35 M | -1.28 M | - | -1.81 M | -701 K | -564 K | - | -392 K | -390 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 779 K | 297 K | 16.8 K | - | -97.7 K | 21.4 K | -114 K | - | 22.6 K | -18.8 K | 141 K | - | 14.8 K | 154 K | -141 K | - | 57.6 K | 52.4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-6.05 M | -6 M | -8.95 M | - | -6.75 M | -7.77 M | -8.27 M | - | -9.88 M | -7.34 M | -9.93 M | - | -8.64 M | -11.7 M | -9.63 M | - | -6.22 M | -3.72 M | 10.1 M | - | 13.9 M | 11.9 M | 10.4 M | - | 12.1 M | 14.7 M | -1.06 M | - | -1.63 M | -1.35 M | -1.24 M | - | -1.65 M | -1.34 M | -1.27 M | - | -1.79 M | -690 K | -555 K | - | -385 K | -381 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
6.25 M | 6.32 M | 9.16 M | - | 7.13 M | 8.19 M | 8.58 M | - | 10.6 M | 10.1 M | 10.5 M | - | 11.1 M | 11.7 M | 10.1 M | - | 10.9 M | 8.25 M | 9.59 M | - | 13.2 M | 13.1 M | 6.42 M | - | 3.96 M | 3.36 M | 2.15 M | - | 1.67 M | 1.39 M | 1.26 M | - | 1.67 M | 1.36 M | 1.29 M | - | 1.81 M | 703 K | 564 K | - | 392 K | 390 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
1.87 M | 1.5 M | 2.5 M | - | 1.82 M | 2.6 M | 2.77 M | - | 4.29 M | 3.13 M | 2.92 M | - | 3.15 M | 3.71 M | 3.01 M | - | 3.62 M | 2.47 M | 2.92 M | - | 2.92 M | 2.47 M | 2.94 M | - | 2.2 M | 2.19 M | 1.46 M | - | 1.06 M | 808 K | 640 K | - | 1.15 M | 849 K | 882 K | - | 1.41 M | 382 K | 226 K | - | 183 K | 187 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Co-Diagnostics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |  USA |
 |
Waters Corporation
WAT
|
$ 476.29 | -0.09 % | $ 28.4 B | USA |
 |
Exagen
XGN
|
$ 5.26 | -25.92 % | $ 113 M | USA |
 |
Celcuity
CELC
|
$ 67.13 | -4.11 % | $ 3.14 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 370.89 | -0.25 % | $ 30.9 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 101.65 | 0.63 % | $ 6.86 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
$ 664.97 | -1.18 % | $ 19.2 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 346.21 | -2.02 % | $ 17.2 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 750.2 | -0.69 % | $ 36.1 B |  Schweiz |
 |
Danaher Corporation
DHR
|
$ 236.19 | 0.46 % | $ 168 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 30.39 | -1.32 % | $ 28.8 B |  Niderland |
 |
RadNet
RDNT
|
$ 77.91 | -0.6 % | $ 5.86 B | USA |
 |
Senseonics Holdings
SENS
|
$ 10.05 | 2.55 % | $ 419 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | -7.8 % | $ 133 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 719.09 | -0.35 % | $ 271 B | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
$ 155.43 | -2.12 % | $ 19.5 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
$ 10.63 | -8.68 % | $ 361 M |  Israel |
 |
VolitionRx Limited
VNRX
|
$ 0.19 | -6.2 % | $ 23.9 M |  Singapore |
 |
Natera
NTRA
|
$ 311.81 | -1.92 % | $ 42.6 B | USA |
 |
IQVIA Holdings
IQV
|
$ 275.46 | -1.21 % | $ 47.4 B | USA |
 |
Agilent Technologies
A
|
$ 178.84 | -0.74 % | $ 50.8 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
DexCom
DXCM
|
$ 79.92 | -1.42 % | $ 31.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 258.38 | -0.5 % | $ 28.7 B | USA |
 |
Castle Biosciences
CSTL
|
$ 34.41 | 0.07 % | $ 997 M | USA |
 |
IDEXX Laboratories
IDXX
|
$ 696.77 | -1.4 % | $ 56 B | USA |
 |
Illumina
ILMN
|
$ 214.84 | -2.69 % | $ 33.3 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.05 | -3.48 % | $ 99 K | USA |
|
Biodesix
BDSX
|
$ 10.04 | -2.95 % | $ 75.8 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.25 | 7.66 % | $ 6.81 M | USA |
 |
Bioventus
BVS
|
$ 11.18 | 1.5 % | $ 745 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 25.83 | -1.22 % | $ 795 M | USA |
 |
CareDx, Inc
CDNA
|
$ 80.78 | -4.31 % | $ 4.3 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Britain |
 |
Biomerica
BMRA
|
$ 1.48 | -4.52 % | $ 4.31 M | USA |